Pharmaron Beijing Gestione

Gestione criteri di controllo 4/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Boliang Lou

Amministratore delegato

CN¥2.2m

Compenso totale

Percentuale dello stipendio del CEO	95.1%
Mandato del CEO	8.1yrs
Proprietà del CEO	n/a
Durata media del management	8.1yrs
Durata media del Consiglio di amministrazione	8.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Boliang Lou rispetto agli utili di Pharmaron Beijing?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	CN¥2b
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥1b
Dec 31 2023	CN¥2m	CN¥2m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥1b
Jan 01 2023	n/a	n/a	CN¥1b
Sep 30 2022	n/a	n/a	CN¥2b
Jun 30 2022	n/a	n/a	CN¥2b
Mar 31 2022	n/a	n/a	CN¥2b
Dec 31 2021	CN¥8m	CN¥2m	CN¥2b
Sep 30 2021	n/a	n/a	CN¥1b
Jun 30 2021	n/a	n/a	CN¥1b
Mar 31 2021	n/a	n/a	CN¥1b
Dec 31 2020	CN¥4m	CN¥2m	CN¥1b
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥865m
Mar 31 2020	n/a	n/a	CN¥594m
Dec 31 2019	CN¥3m	CN¥2m	CN¥547m
Sep 30 2019	n/a	n/a	CN¥437m
Jun 30 2019	n/a	n/a	CN¥378m
Mar 31 2019	n/a	n/a	CN¥346m
Dec 31 2018	CN¥3m	CN¥2m	CN¥333m

Compensazione vs Mercato: La retribuzione totale di Boliang ($USD 304.93K ) è circa la media per le aziende di dimensioni simili nel mercato CN ($USD 264.94K ).

Compensazione vs guadagni: La retribuzione di Boliang è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Boliang Lou (61 yo)

8.1yrs

Mandato

CN¥2,208,000

Compensazione

Dr. Boliang Lou, Ph D serves as Chairman of the Board and Chief Executive Officer at Pharmaron, Inc. He is a Co-Founder at Pharmaron, Inc. Dr. Lou serves as the Chairman, Chief Executive Officer and Manage...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Boliang Lou	Chairman & CEO	no data	CN¥2.21m	Nessun dato
Xiaoqiang Lou	Co-Founder	8.1yrs	CN¥1.91m	5.66% CN¥ 2.5b
Bei Zheng	Executive VP & Executive Director	8.1yrs	CN¥1.60m	2.12% CN¥ 940.8m
Shing Chung Li	CFO & Secretary of the Board	no data	CN¥1.96m	Nessun dato
Hua Yang	Chief Scientific Officer & Deputy Manager	8.1yrs	CN¥1.85m	Nessun dato
Connie Sun	Senior VP & Global Head of Business Development of Small Molecules	no data	Nessun dato	Nessun dato
Celina Zhong	Senior Vice President of Human Resources	no data	Nessun dato	Nessun dato
Katherine Lee	Chief Business Officer	13.8yrs	Nessun dato	Nessun dato
Stephen Lewinton	Senior Vice President of UK Operations	no data	Nessun dato	Nessun dato
Jingqi Huang	Senior Vice President of In Vivo Pharmacology	no data	Nessun dato	Nessun dato
Mandy Xu	Senior Vice President of DMPK	2.9yrs	Nessun dato	Nessun dato
Sid Bhoopathy	Senior VP and US Head of Laboratory Services & CGT	3yrs	Nessun dato	Nessun dato

8.1yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di 300759 è esperto e expertise (durata media dell'incarico 8.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Boliang Lou	Chairman & CEO	8.1yrs	CN¥2.21m	Nessun dato
Xiaoqiang Lou	Co-Founder	8.1yrs	CN¥1.91m	5.66% CN¥ 2.5b
Bei Zheng	Executive VP & Executive Director	8.1yrs	CN¥1.60m	2.12% CN¥ 940.8m
Kexin Yang	Chairman of the Supervisory Committee	8.1yrs	Nessun dato	Nessun dato
Jiaqing Li	Non Executive Director	8.1yrs	Nessun dato	Nessun dato
Kwan Hung Tsang	Independent Non Executive Director	5yrs	CN¥300.00k	Nessun dato
Lan Zhang	Employee Representative Supervisor	8.1yrs	Nessun dato	Nessun dato
Lihua Li	Independent Non Executive Director	2.2yrs	CN¥300.00k	0.0042% CN¥ 1.9m
Jian Yu	Independent Non Executive Director	4.3yrs	CN¥300.00k	Nessun dato
Shu Feng	Supervisor	3.9yrs	Nessun dato	Nessun dato
Qilin Zhou	Independent Non-Executive Director	2.2yrs	CN¥300.00k	Nessun dato

8.1yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 300759 sono considerati esperti (durata media dell'incarico 8.1 anni).

Pharmaron Beijing Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024

Pharmaron Beijing Co., Ltd. Announces Executive Changes

President recently sold CN¥231m worth of stock

Executive VP & Executive Director recently sold CN¥22m worth of stock

President recently sold CN¥13m worth of stock

Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 21, 2023

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.20 in 3Q 2023)

Investor sentiment deteriorates as stock falls 22%

Pharmaron Beijing Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.25 in 2Q 2023)

Pharmaron Beijing Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.

Pharmaron Beijing Co., Ltd. Approves Final Dividend for the Financial Year Ended December 31, 2023, Payable on July 26, 2024

Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024

Pharmaron Beijing Co., Ltd. (SZSE:300759) announces an Equity Buyback for CNY 300 million worth of its shares.

First quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.20 in 1Q 2023)

Pharmaron Beijing Co., Ltd. Announces Executive Changes

Pharmaron Beijing Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: EPS: CN¥0.90 (vs CN¥0.78 in FY 2022)

Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023

Investor sentiment deteriorates as stock falls 17%

Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023

New major risk - Share price stability

Now 23% undervalued after recent price drop

Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Third quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.21 in 3Q 2022)

President recently sold CN¥231m worth of stock

Executive VP & Executive Director recently sold CN¥22m worth of stock

Second quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.19 in 2Q 2022)

Pharmaron Beijing Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 27, 2023

President recently sold CN¥13m worth of stock

Pharmaron Beijing Co., Ltd. Approves Cash Dividend for 2022

Investor sentiment deteriorates as stock falls 16%

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 21, 2023

First quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.21 in 1Q 2022)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 15%

Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2022

Executive VP & Executive Director recently sold CN¥21m worth of stock

President recently sold CN¥31m worth of stock

President recently sold CN¥72m worth of stock

President recently sold CN¥24m worth of stock

President recently sold CN¥41m worth of stock

President recently sold CN¥48m worth of stock

President recently sold CN¥131m worth of stock

Less than half of directors are independent

Investor sentiment improved over the past week

Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into equity transfer agreement to acquire 21.6874% stake in Pharmaron (Chengdu) Clinical Services Co., Ltd from Mr. Yu Wu and Mr. Li Xianghao for RMB 506.79 million.

Third quarter 2022 earnings released

Investor sentiment improved over the past week

Pharmaron Beijing Co., Ltd. to Report Nine Months, 2022 Results on Oct 27, 2022

Pharmaron Beijing Co., Ltd. Announces Board Appointments

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.27 in 2Q 2021)

Pharmaron Beijing Co., Ltd. Announces Board Changes

Pharmaron Beijing Co., Ltd. to Report First Half, 2022 Results on Aug 29, 2022

Investor sentiment deteriorated over the past week

Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for Period from January 1, 2022 to June 30, 2022

Pharmaron Beijing Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on June 14, 2022

Pharmaron Beijing Co., Ltd. Approves Cash Dividend, Payable on 12 July 2022

Pharmaron Beijing Co., Ltd. Approves Cash Dividend

Pharmaron Beijing Co., Ltd. (SZSE:300759) has entered into a definitive Asset Purchase Agreement to acquire Coventry API manufacturing site of Noramco, Inc.

Pharmaron Beijing Co., Ltd. (SZSE:300759) has entered into a definitive Asset Purchase Agreement to acquire Coventry API manufacturing site of Noramco, Inc.

Pharmaron Beijing Co., Ltd. (SZSE:300759) completed the acquisition of 100% equity interest in Beijing Anikeepter Biotech Co from Chen Jing and Chen Xuejun for CNY 85.34 million.

Pharmaron Beijing Co., Ltd., Annual General Meeting, May 31, 2022

Pharmaron Beijing Co., Ltd. Proposes Final Cash Dividend for the Financial Year Ended December 31, 2021

First quarter 2022 earnings released

Less than half of directors are independent

Pharmaron Beijing Co., Ltd. to Report Q1, 2022 Results on Apr 28, 2022

Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into conditional agreement to acquire 100% equity interest in Beijing Anikeepter Biotech Co from Chen Jing and Chen Xuejun RMB 83.60 million.

Pharmaron Beijing Co., Ltd. proposes Final Dividend for the Year Ended December 31, 2021